NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Dec. 16, 2005--Senesco Technologies, Inc. (“Senesco” or the “Company”) (AMEX:SNT) today announced results from the Company’s funded research agreement at Mayo Clinic. Using human multiple myeloma cells grown in vitro, the data show that the Company’s proprietary Factor 5A gene technology causes these cancer cells to die, thereby leaving fewer viable cancer cells in comparison to untreated samples.
